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(MACOP-B), might be superior to those of CHOP regimens.(5, 7-10) High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) was also associated with encouraging results (PFS of more than 75% for newly diagnosed PMBL patients). (3, 11, 12) These reports indicate that intensive regimens might be beneficial in a certain proportion of PMBL patients.
In the rituximab era, the combination of rituximab and chemotherapy has improved outcomes in various subtypes of B-cell lymphoma. (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) In the literature, more than 80% of patients with PMBL receiving immunochemotherapy with or without radiotherapy (RT) also achieved long-term overall survival (OS). outcomes were reported from a phase 2 trial, the regimen might be a promising treatment strategy to reduce the risk of RT. Meanwhile, the DA-EPOCH-R regimen is somewhat complicated and expensive, requiring continuous infusion for 96 hours in each cycle and frequent evaluation of complete blood counts. Considering R-CHOP-based regimens without RT could provide curative potential for a significant proportion of PMBL patients without hospitalization, (19, 21) it would be beneficial to identify the subset of patients that could be cured with this treatment strategy.
The goal of the present multicenter cooperative retrospective study in Japan was to investigate the optimal treatment strategy for PMBL patients by evaluating the clinical outcomes in response to various treatments and to assess a risk-stratified treatment strategy to minimize the risk of late adverse events in PMBL patients.
Methods

Patients
A total of 363 patients with PMBL that was newly diagnosed between May 1986 and September 2012 at one of any of 65 participating hospitals in Japan were retrospectively analyzed. We registered consecutive patients who were diagnosed with PMBL at each institution in accordance with the WHO classification. were not available for the central review, the histological diagnosis of PMBL was re-confirmed by a pathologist at an each institution, according to the current WHO classification. Therefore, 345 patients were finally analyzed in the present study.
Patients were treated according to each institution's treatment standards. The study protocol was approved by the institutional review boards of Nagoya Daini Red Cross Hospital (where this study was organized) and of each participating hospital. The study complied with all the provisions of the Declaration of Helsinki.
Immunohistochemistry
Immunohistochemistry was performed using formalin-fixed, paraffin-embedded tissue sections using the avidin-biotin peroxidase complex method. Monoclonal antibodies targeting the following proteins were used: CD20, CD30, CD3, CD10, BCL6, MUM1
and CD15 (Dako). In addition, programmed cell death ligand-1 (PDL1) was evaluated, second/third-generation chemotherapeutic regimens other than CHOP-or R-CHOP-based regimens as the first-line treatment. In terms of HDT/ASCT as the first-line treatment, the treatments were performed at 13 institutions. Consolidative RT was performed according to the treatment strategy used at each institution.
Response assessment
Clinical data were collected from case report forms. In principle, an effusion was evaluated by CT and/or echocardiography, as per the usual pretreatment evaluation.
Responses were evaluated by each investigator in accordance with the 1999
International Workshop Criteria (32).
Statistical analysis
OS was defined as the period from diagnosis to death or last follow-up. Progression-free survival (PFS) was defined as the period from diagnosis to disease progression, relapse, death from any cause, or last date of follow-up. Patients who did not achieve a CR or PR were considered to have primary refractory disease. Early relapse was defined as relapse occurring less than 12 months after diagnosis. PFS and OS were analyzed using Kaplan-Meier methods, and results were compared using the log-rank test. Univariate and multivariate Cox regression analyses were performed to assess the effects of prognostic factors. Multivariate analysis was built with a forward/backward, stepwise method using threshold values for removal from and addition to the model of P = 0.20
and P = 0.05, respectively. The individual factors of IPI were entered into the model in multivariate analysis. All probability values were two-sided and had an overall significance level of 0.05. Statistical analyses were performed with Stata SE 12 software (StataCorp LP, College Station, TX).
Results
Patient characteristics
Patient characteristics are summarized in 
Treatment regimen
In all, 267 patients received rituximab-containing chemotherapy. CHOP and R-CHOP in Japan, the use of rituximab-containing regimens rapidly increased, as shown in Supplementary Table S1 . The use of HDT/ASCT and radiation therapy after initial treatment decreased moderately. The DA-EPOCH-R regimen was selected in the latest period.
Clinical outcomes
With a median follow-up of 48 months in surviving patients, the OS and PFS at 4 years were 87% and 70%, respectively ( Figure 1A and 1B). The OS and PFS of patients treated with rituximab-containing chemotherapy were superior to those of patients receiving chemotherapy without rituximab (4-year OS: 91% vs. 77%, P < 0.001 and 4-year PFS: 75% vs. 54%, P < 0.001, respectively). The risk of CNS relapse did not differ for patients treated with or without rituximab as first-line treatment (3.8% vs.
1.3%, P = 0.251). The OS at 4 years for patients treated with CHOP, R-CHOP, DA-EPOCH-R, the 2 nd /3 rd -generation regimens, and HDT/ASCT was 67%, 90%, 100%, 91% and 92%, respectively, with a median follow-up durations of 118 months, 36 months, 19 months, 48 months and 101 months, respectively (P < 0.001) ( Figure 1C ); PFS at 4 years was 40%, 71%, 100%, 83% and 76%, respectively (P < 0.001) ( Figure   1D ).
Second malignancies and cardiac toxicity developed after treatment in seven and 10 patients, respectively. The median age of these 17 patients was 62 years. 
Patient characteristics and clinical outcomes in the R-CHOP group
Detailed characteristics of patients in the R-CHOP group are shown in supplementary Table S2 . We divided this group into four subgroups according to the disease status after R-CHOP or R-CHOP-like regimen and the presence or absence of consolidative RT:
namely, R-CHOP+RT with residual mass, R-CHOP+RT in CR, R-CHOP with residual mass and R-CHOP in CR. Among the 187 patients in the R-CHOP group, 64 patients received consolidative RT after R-CHOP (Supplementary Table S3 ). Elderly age and higher IPI were less common in those who received consolidative RT. Thirty-three of 64 patients received consolidative RT with residual mass after R-CHOP, while 31 of 64 patients received RT in CR after R-CHOP. Among the remaining 123 patients without consolidative RT, 34 patients did not achieve CR after R-CHOP, and 89 patients were in CR after R-CHOP, respectively. Among 34 patients with residual mass who were treated with R-CHOP, 16 patients developed progressive disease (PD), and four patients received follow-up without RT based on the negative findings on PET/CT after the initial series of treatment. Of 89 patients who achieved a CR after R-CHOP but did not receive RT, 14 patients experienced relapse. Among these 14 patients, nine patients developed the relapsed disease in their mediastinum, while the remaining five patients relapsed in other sites. The OS and PFS at 4 years of patients receiving consolidative RT were 100% and 85%, respectively, in the group with residual mass and were 96% and 90%, respectively, in the group in CR (P = 0.15; OS, P = 0.80; PFS) (Supplementary Figure S1 and S2). Meanwhile, the OS and PFS at 4 years of patients who did not receive consolidative RT were 64% and 35%, respectively, in the group with residual mass without disease progression and 95% and 77%, respectively, in the group in CR (P < 0.001; OS, P < 0.001; PFS). Taken together, these data indicated that a significant proportion of patients achieving CR after R-CHOP can be cured without consolidative RT.
Prognostic factors and survival for patients treated with R-CHOP and without consolidative RT
One hundred and twenty-three patients receiving R-CHOP without consolidative RT were analyzed. The analysis of potential prognostic factors is shown in Table 2 . On univariate analysis, the presence of pleural or pericardial effusion, PS more than 1 and higher IPI were adverse prognostic factors for OS, and the presence of pleural or pericardial effusion, advanced stage, extranodal involvement, PS, LDH, soluble interleukin-2 receptor (sIL-2R), and higher IPI were adverse prognostic factors for PFS.
On multivariate analysis, we could not identify significant prognostic factors for OS.
The presence of pleural or pericardial effusion [hazard ratio (HR), 3.53; 95% confidence interval (CI), 1.69-7.40; P = 0.001] and advanced stage (stage III/IV; HR, 2.16; 95% CI, 1.14-4.11; P = 0.018) were identified as adverse prognostic factors for PFS. As almost all the patients with progression after R-CHOP developed disease within 12 months after diagnosis, we performed Cox regression analyses to determine the predictive factors for primary refractory or early relapse within 12 months after diagnosis. On multivariate analysis, only the presence of pleural or pericardial effusion was predictive of primary refractory or early relapse within 12 months (HR, 6.11; 95% CI, 2.30-16.24; P < 0.001). In this cohort, only five (8%) of 65 patients without pleural or pericardial effusion experienced primary refractory or early relapse within 12 months; meanwhile, 25 (43%) of 58 patients with pleural or pericardial effusion (P < 0.001) had refractory or early relapsed disease.
As IPI and the presence of pleural or pericardial effusion were prognostic factors for OS on univariate analysis and these were not related (correlation coefficient = 0.39), the OS and PFS in patients receiving R-CHOP without RT were analyzed according to these prognostic factors. The OS and PFS in patients receiving R-CHOP without RT were analyzed according to the presence of pleural or pericardial effusion and IPI. As expected ( Figure 2A and 2B), the best OS and PFS were observed in patients with low IPI and without the pleural or pericardial effusion. The OS and PFS at 4 years of these 58 patients were 95% and 87%, respectively. Meanwhile, based on individual factors of LDH, B symptom and pleural or pericardial effusion identified on multivariate analysis for PFS, the OS and PFS were also analyzed (supplemental Figure 3 and 4). Although the OS and PFS could be stratified well, the number of patients categorized into the low-risk category was lower than that of patients under the stratification using IPI and effusion. Taken together, these data indicated that a significant proportion of patients with low IPI and without pleural or pericardial effusion at the time of diagnosis can be potentially cured by the R-CHOP regimen without consolidative RT.
Meanwhile, the treatment should be considered for patients with higher IPI and the presence of pleural or pericardial effusion. As shown in Figure 2C and 2D, the outcomes of R-CHOP were not satisfactory in patients with higher IPI and/or the presence of pleural or pericardial effusion (4-year OS: 97% vs. 81%, P = 0.004 and 4-year PFS: 89% vs. 54%, P < 0.001, respectively).
Discussion
It is important to establish a more effective and less toxic standard treatment for PMBL, as affected patients tended to be young and can be cured when properly treated.
The present study investigated a larger cohort when compared with other studies and indicated that almost all PMBL patients with lower IPI and the absence of the pleural or pericardial effusion could be cured by the R-CHOP regimen without consolidative RT.
Considering the excellent outcomes of the recent promising regimen, DA-EPOCH-R reported by Dunleavy et al., (27) clinical practice at this time. Further study of the utility of these biologic tools is necessary to improve diagnosis and management of this disease.
In conclusion, the present study demonstrated that IPI and the presence of pleural or pericardial effusion were adverse prognostic factors for risk-stratification of PMBL patients treated with R-CHOP. R-CHOP without consolidative RT can achieve a high rate of cure for approximately one-half of PMBL patients, while alternative regimens, including DA-EPOCH-R, should be offered to remaining patients. Prospective studies to validate these prognostic factors and a risk-adopted treatment strategy are warranted.
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